Clinical Trials Logo

Plasma Cell Myeloma clinical trials

View clinical trials related to Plasma Cell Myeloma.

Filter by:

NCT ID: NCT03942224 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma

DeRIVE
Start date: May 1, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well daratumumab, ixazomib, and dexamethasone with or without bortezomib work in treating patients with newly diagnosed multiple myeloma. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib, dexamethasone, and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving daratumumab, ixazomib, and dexamethasone with or without bortezomib may work better in treating patients with multiple myeloma.

NCT ID: NCT03941860 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Lenalidomide With or Without Ixazomib in Treating Patients With Evidence of Residual Multiple Myeloma After Stem Cell Transplant

Start date: May 29, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplant. Immunotherapy with lenalidomide may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplant.

NCT ID: NCT03870633 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma

Start date: March 15, 2019
Phase:
Study type: Observational

This trial studies financial difficulty in participants with chronic lymphocytic leukemia and multiple myeloma. Assessment of financial difficulty may help to better understand the financial impact of cancer and come up with ways to help participants avoid financial problems during treatment.

NCT ID: NCT03870451 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

Start date: May 31, 2019
Phase: N/A
Study type: Interventional

This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in hands or feet) is a common side effect of chemotherapy such as bortezomib that affects the quality of life and amount of chemotherapy that can be given to many cancer patients. Cryocompression is a treatment where a glove and a boot are worn to cool down the skin. This cooling treatment is safe and does not interfere with chemotherapy treatment. Daily cryocompression therapy may reduce neuropathy caused by bortezomib chemotherapy.

NCT ID: NCT03858205 Recruiting - Plasma Cell Myeloma Clinical Trials

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Start date: March 11, 2019
Phase: N/A
Study type: Interventional

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.

NCT ID: NCT03793907 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Strength Training in Improving Quality of Life in Patients With Multiple Myeloma

Start date: May 31, 2019
Phase: N/A
Study type: Interventional

This trial studies how well strength training works in improving quality of life in patients with multiple myeloma. Weekly physical activity may improve bone recovery, reduce pain, and increase quality of life in patients with multiple myeloma.

NCT ID: NCT03756896 Recruiting - Plasma Cell Myeloma Clinical Trials

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

Start date: January 25, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well carfilzomib, pomalidomide, and dexamethasone work in treating patients with high-risk multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib, pomalidomide, and dexamethasone may work better in treating patients with multiple myeloma.

NCT ID: NCT03622788 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant

Start date: July 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies how well cytokine-treated veto cells work in treating participants with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant, they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. cytokine-treated veto cells may help the transplanted donor cells to develop and grow in recipients without causing graft-versus-host-disease (GVHD - when transplanted donor tissue attacks the tissues of the recipient's body).

NCT ID: NCT03477539 Recruiting - Plasma Cell Myeloma Clinical Trials

Daratumumab in Treating Transplant-Eligible Participants With Multiple Myeloma

Start date: April 9, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well daratumumab works in treating transplant-eligible participants with multiple myeloma. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT03346135 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Start date: July 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.